Vectura wins additional $10m patent damages against GSK
16-09-2019
GSK awarded Arrow declaration in patent dispute with Vectura
17-12-2018
Vectura sues GSK for patent infringement
29-07-2016
Willy Barton / Shutterstock.com
British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Vectura, GlaxoSmithKline, Ellipta, asthma, patent infringement, chronic obstructive pulmonary disease, damages, royalties, Delaware
